Konstantin Seitzer
Overview
Explore the profile of Konstantin Seitzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
65
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wustmann N, Humberg V, Vieler J, Seitzer K, von Ruden S, Juratli M, et al.
Lab Invest
. 2024 Sep;
104(10):102142.
PMID: 39307310
Circulating tumor cells and liquid biopsy-based biomarkers might one day play a crucial role in the treatment decision process for patients of several cancer entities. However, clinical studies on liquid...
2.
Seifert R, Rasul S, Seitzer K, Eveslage M, Rahbar Nikoukar L, Kessel K, et al.
Radiology
. 2023 Apr;
307(4):e222010.
PMID: 37070991
Background Prostate-specific membrane antigen (PSMA) PET has high specificity in localizing primary tumors and metastases in patients with prostate cancer, but the individual overall survival probability is still difficult to...
3.
Wustmann N, Seitzer K, Humberg V, Vieler J, Grundmann N, Steinestel J, et al.
Biomark Res
. 2023 Apr;
11(1):37.
PMID: 37016463
Background: Androgen receptor (AR) splice variants (AR-Vs) have been discussed as a biomarker in prostate cancer (PC). However, some reports question the predictive property of AR-Vs. From a mechanistic perspective,...
4.
Schlack K, Seitzer K, Wustmann N, Humberg V, Grundmann N, Steinestel J, et al.
Sci Rep
. 2022 Jul;
12(1):11846.
PMID: 35831403
Biomarker in metastatic castration resistant prostate cancer (mCRPC) treatment are rare. We aimed to compare the clinical value of circulating tumor cells (CTCs) and androgen receptor splice variant 7 (AR-V7)...
5.
Seifert R, Seitzer K, Herrmann K, Kessel K, Schafers M, Kleesiek J, et al.
Theranostics
. 2020 Jul;
10(17):7812-7820.
PMID: 32685021
PSMA-PET-CT enables measuring molecular expression of prostate-specific membrane antigen (PSMA) , which is the target molecule of Lu-PSMA-617 (Lu-PSMA) therapy. However, the correlation of PSMA expression and overall survival (OS)...